Once hyped and then humbled, the microbiome therapeutics field is entering a promising new phase, driven by FDA approvals, improved clinical trial outcomes (particularly in C. difficile and GvHD), and advances in manufacturing and automation. Despite ongoing regulatory and commercialization hurdles, the sector is poised to evolve from a niche concept into a foundational pillar of precision medicine, offering scalable, data-driven treatments for complex conditions like IBD and metabolic disorders.
Keep Reading
Add A Comment